ENResearchers and medical specialists at Universitätsmedizin Mainz, in collaboration with hospital centers in Dresden, Münster, and Dortmund, have announced successful results from the first human clinical trial evaluating activated regulatory T cells, known as ATregs or Actileucel. Developed by ActiTrexx GmbH, this experimental cellular therapy uses regulatory T cells derived from healthy, unrelated blood donors to prevent severe acute graft-versus-host disease following allogeneic stem cell transplantation. By activating donor cells within sixteen hours instead of culturing them for weeks in a laboratory, the clinical team was able to administer the treatment within twenty-four hours of production. The initial Phase I/II study demonstrated exceptional safety and tolerability, opening new avenues for patients with blood cancers seeking cutting-edge cellular therapy in Germany.
The Challenge of Stem Cell Transplantation and Graft-Versus-Host Disease
Allogeneic stem cell transplantation offers the primary potential for a permanent cure in many patients diagnosed with aggressive blood cancers, including acute leukemias and severe bone marrow failure syndromes. During this intensive procedure, the patient receives healthy blood-forming stem cells from a matched donor after undergoing conditioning therapy with chemotherapy or radiation to eliminate malignant cells. Although this approach offers a life-saving opportunity for long-term remission, it carries substantial risks of severe immunological complications due to interactions between the donor immune system and recipient tissues.
The most critical acute complication following transplantation is acute graft-versus-host disease, commonly abbreviated as aGvHD. This condition develops when immune cells present within the donor stem cell graft identify the recipient’s healthy organ proteins as foreign targets and initiate an immune attack. The primary organs affected by aGvHD include the skin, liver, and gastrointestinal tract, causing severe skin rashes, jaundice, and dangerous intestinal inflammation. In severe cases, acute graft-versus-host disease can be life-threatening and significantly undermines the overall success of the transplant.
Naturally occurring regulatory T cells, often referred to as Tregs, act as physiological brakes within the human immune system, maintaining immune tolerance and preventing autoimmune tissue destruction. Clinicians have long recognized that administering additional regulatory T cells can suppress harmful immune responses in graft-versus-host disease. However, conventional protocols required isolating these specialized cells directly from the matched stem cell donor and expanding them for several weeks in complex laboratory processes. This prolonged manufacturing timeline made regulatory T cell therapy impractical for most acutely ill patients requiring immediate post-transplant intervention.
The ATreg Principle: Rapid Activation Instead of Weeks of Culturing
To overcome the major manufacturing delays associated with conventional cell therapy, researchers at ActiTrexx GmbH in Mainz developed an innovative method focused on cell activation rather than expansion. Instead of relying on multi-week laboratory cell proliferation, the ATreg technology isolates regulatory T cells from standard blood donations provided by healthy, unrelated voluntary donors. These third-party cells undergo a patented sixteen-hour stimulation process that dramatically enhances their natural capacity to promote immune tolerance.
Preclinical studies demonstrated that this brief activation significantly amplifies the protective properties of regulatory T cells, allowing clinicians to achieve therapeutic efficacy with a substantially lower cell dose. Because the cell source is independent of the specific stem cell donor, the ATreg formulation, designated Actileucel, can be produced rapidly on demand. Once activated, the cells are ready for infusion within twenty-four hours, transforming a tailor-made, weeks-long production process into a rapidly deployable cellular product.
The scientific framework behind this procedure was established by Prof. Dr. Andrea Tüttenberg, co-founder, CEO, and Medical Director of ActiTrexx GmbH and researcher at the Department of Dermatology at Universitätsmedizin Mainz, alongside Dr. Helmut Jonuleit, co-founder, CSO, and Director of Research at the same department. Their work received crucial funding support from the Federal Ministry of Education and Research through the GO-Bio program. Their findings confirmed that genetic mismatch between the blood donor and recipient does not hinder the activated cells from effectively suppressing adverse immune reactions.
Key Findings from the ATreg-001 Clinical Trial
The prospective, open-label, single-arm Phase I/II clinical trial, designated ATreg-001 and registered under EU CT Number 2024-516599-14-00, evaluated ten patients across four leading medical centers in Germany. Participating institutions included Universitätsmedizin Mainz under lead principal investigator Dr. E. M. Wagner-Drouet, University Hospital Dresden led by Prof. Dr. M. Wermke, University Hospital Münster under Prof. Dr. M. Stelljes, and St. Johannes Hospital Dortmund led by PD Dr. R. G. Meyer. The study protocol was approved by the Paul-Ehrlich-Institut and local ethics committees.
Approximately ten days following their stem cell transplants, patients received an infusion of ATreg cells alongside standard immunosuppressive medication. The study utilized a dose-escalation design across three consecutive dose levels to rigorously assess clinical safety, feasibility, and tolerability. Despite receiving cells derived from genetically mismatched blood donors, patients experienced no severe infusion-related side effects or immediate toxicities during or after administration.
The clinical outcomes evaluated during the mandatory one-hundred-day post-transplant observation window exceeded initial safety expectations. All ten patients demonstrated successful engraftment of their donor stem cells, confirming that ATreg administration did not interfere with bone marrow reconstitution. Furthermore, no patient developed severe Grade 3 or 4 acute graft-versus-host disease, and zero transplant-related mortality was recorded. These results validate the high feasibility and favorable safety profile of this activated cell product.
Implications for International Patients Seeking Medical Treatment in Germany
For international patients traveling to Germany for advanced stem cell transplantation, the successful completion of the ATreg-001 trial represents an encouraging step forward. Graft-versus-host disease remains one of the primary obstacles to uneventful recovery following allogeneic stem cell procedures, often leading to extended hospitalization and secondary complications. The capability to manufacture a protective cellular treatment within twenty-four hours using standard blood donor donations could significantly reduce severe post-transplant risks.
Furthermore, as emphasized by Dr. Helmut Jonuleit, effective control of immunological complications through activated regulatory T cells may eventually simplify the donor selection process. If adverse immune responses can be reliably mitigated using off-the-shelf activated cells, strict genetic matching requirements between donors and recipients might become less restrictive. This shift could help broaden the donor pool for patients with rare tissue types who face difficulties finding fully matched stem cell donors.
Patients and families should keep in mind that ATreg therapy is currently an investigational treatment moving into subsequent clinical study phases. The research team is preparing a randomized controlled follow-up trial involving a larger patient population to evaluate efficacy against standard prophylactic regimens. International patients undergoing treatment at German university hospitals can consult their treating hematologists regarding eligibility for ongoing cellular therapy studies.
Source: Universitätsmedizin der Johannes Gutenberg-Universität Mainz